RCT Comparing Invisalign and Traditional Orthodontic Treatment
Launched by TEXAS A&M UNIVERSITY · Sep 18, 2020
Trial Information
Current as of May 07, 2025
Completed
Keywords
ClinConnect Summary
Patients were selected based on being adults and having mild Class I malocclusion. They were randomly allocated into either the aligner group and the traditiona (clear braces group).. The aligner group was treated with invisalign, with up to two adjustments at the end of treatment. The traditional group had clear braces placed on their teeth. The outcome variables including the following: 1) pain and discomfort related to treatment, 2) posttreatment occlusal status, and 3) postretention occlusal status.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Class I molar and canine relationships
- • 2. Non-extraction treatments
- • 3. Mandibular crowding of 4 mm or less
- • 4. No missing tooth (from second to second molar)
- Exclusion Criteria:
- • 1. Anterior or posterior crossbites
- • 2. Anterior or lateral open bites
- • 3. Maxillary overjet exceeding 3mm
- • 4. Impacted tooth
About Texas A&M University
Texas A&M University, a leading research institution located in College Station, Texas, is dedicated to advancing knowledge and innovation in various fields, including health sciences. As a prominent clinical trial sponsor, Texas A&M University leverages its extensive resources and expertise to conduct rigorous research aimed at improving patient outcomes and addressing critical health challenges. The university fosters collaboration among multidisciplinary teams of researchers, clinicians, and students, ensuring a comprehensive approach to clinical trials that emphasizes ethical standards, scientific integrity, and community impact. Through its commitment to advancing medical research, Texas A&M University plays a vital role in the development of novel therapies and interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dallas, Texas, United States
Patients applied
Trial Officials
Peter Buschang, PhD
Principal Investigator
TAMU Health Science Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials